Walmart debuted a nationwide pharmacist training program Dec. 1 for educating its staff on HIV prevention and treatment strategies, which is part of the chain's partnership with the Elton John AIDS Foundation. 

Walgreens has been fined 15 times and CVS four times so far in 2022 for violating Maine's staffing and operating hours laws, The Maine Monitor reported Nov. 30. 

The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.

The FDA pulled its emergency use authorization for Eli Lilly's bebtelovimab Nov. 30, which was the only monoclonal antibody treatment to be authorized for COVID-19. 

The FDA approved the first fecal transplant therapy, Rebyota, for people with ongoing Clostridioides difficile, ABC News reported Nov. 30.

The two drugs used in COVID-19 antiviral Paxlovid are safe and effective among pregnant patients — who are at high risk for complications if they contract COVID-19 — researchers from Baltimore-based Johns Hopkins University found. 

Although African trypanosomiasis, also known as sleeping sickness, has fallen in prominence to become extremely rare, the drug acoziborole may help the World Health Organization's goal of eradicating the parasitic disease by 2030, according to researchers. 

Eisai said lecanemab, its Alzheimer's drug candidate that Biogen is co-marketing, did not cause trial participants to hemorrhage and die. 

HHS wants to adjust how disputes about overcharging, duplicate discounts and diversions part of the 340B program are handled, according to a notice posted on the American Hospital Association's website. 

Civica Rx, a 4-year-old, hospital-owned pharmaceutical company, is eyeing big plans for 2023, its president and CEO told Becker's. 

Capital Rx hired Lloyd Fiorini, who previously worked at CVS, Walgreens and OptumRx, to serve as its chief compliance officer, the pharmacy benefit manager said Nov. 29. 

The latest shortage of multiple forms of pediatric medications is only a fraction of the swath of drug shortages, Megan Ranney, MD, a professor of emergency medicine at Providence, R.I.-based Brown University, wrote in an opinion published in CNN Nov. 28. 

Penn Medicine researchers are targeting a "cornucopia of antigens" with mRNA-based technology to develop a universal flu vaccine, and human clinical trials for the 20-subtype candidate are in the works. 

From 2015 to 2020, FDA approvals of "skinny labels" on biosimilars saved Medicare $1.5 billion, according to a study published Nov. 28 in the Journal of the American Medical Association. 

The fill rate for Tamiflu, the nation's most popular flu prescription drug, is nearly 100 percent higher than it was this time last year, but the drugmaker has said it has "sufficient supply."

As specialty drugs become more common, the types and forms of these drugs are changing, and their costs are increasing.

Batesville, Ark.-based White River Medical Center has filed a complaint to its state's insurance department that accuses Novo Nordisk of restricting drugs that are part of the 340B program, the Arkansas Democrat-Gazette reported Nov. 24. 

Henderson, Nev.-based drugmaker Spectrum Pharmaceuticals will reduce three-fourths of its research and development workforce because the FDA declined to approve its lung cancer drug candidate. 

With omicron subvariants BQ.1 and BQ.1.1 accounting for more than half of COVID-19 cases, at least two therapies are on the cusp of losing their mainstay status in the COVID-19 drug market. 

The FDA will investigate the risk of severe hypocalcemia that results in hospitalization and death with Amgen's osteoporosis drug, Prolia (denosumab).